Tranilast

DB07615InvestigationalSmall molecule

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic... Indications for keloid and hypertrophic scar were added in 1993.

Chemical structure of Tranilast
Primary indication
For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.Curator reviewed
Formula / weight
C18H17NO5 · 327.3313 g/mol (avg)
Code names
MK-341

Resolves to

Compound
UNIIHVF50SMY6ECAS53902-12-8ChEMBLCHEMBL415324ChEBI77572PubChem5282230KEGGD02027
Clinical / RWD
RxNorm57330
Structure
InChIKeyNZHGWWWHIYHZNX-CSKARUKUSA-NSMILESCOC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC
Targets
P08842STSP35367HRH1O60760HPGDS

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,227Drug interactionsStructured to mechanism, not free text
Sign in
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tranilast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In